Cerevel jumps as schizophrenia treatment shows promise in trial

Cerevel Therapeutics Holdings

19/12/2022 15:25

** Neuroscience focused biotech firm Cerevel Therapeutics
Holdings Inc's shares  CERE.O  rise 28% at ~$32
    ** Co reports positive results from early-stage
blood-pressure monitoring trial for experimental schizophrenia
treatment, Emraclidine
    ** Schizophrenia is a mental disorder that causes people to
interpret reality abnormally
    ** Data provide clear evidence that the drug does not induce
an increase in blood pressure with chronic dosing in people
living with schizophrenia - CERE 
    ** Co adds that the drug was generally well-tolerated, with
a side effect profile consistent with prior trials
    ** CERE says mid-stage program in schizophrenia on track to
read out in H1 of 2024 
    ** Including session's gain, stock up 0.11% YTD
 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))